NNFN Stock Chart & Stats
€3.36
€0.03(0.81%)
At close: 4:00 PM EDT
€3.36
€0.03(0.81%)
Day’s Range― - ―
52-Week Range€1.93 - €5.24
Previous CloseN/A
Volume0.00
Average Volume (3M)11.00
Market Cap
€1.08B
Enterprise Value€1.06K
Total Cash (Recent Filing)€133.86M
Total Debt (Recent Filing)€436.67M
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Aug 05, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding319,391,000
10 Day Avg. Volume0
30 Day Avg. Volume11
Financial Highlights & Ratios
PEG Ratio-3.54
Price to Book (P/B)-33.97
Price to Sales (P/S)4.97
P/FCF Ratio126.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€7.64Price Target Upside127.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)<0.01
Revenue Forecast (FY)€401.78M
Bulls Say, Bears Say
Bulls Say
High Gross Margins And Scaled RevenueSustained high gross margins (~79% TTM) combined with meaningful revenue scaling provide durable operating leverage. That margin profile supports reinvestment in commercialization and R&D, enabling profitable unit economics as volumes rise and protecting gross-profit against cyclical cost moves.
Improving Operating And Free Cash FlowConsistent positive operating and free cash flow in recent periods underpins financial flexibility. This cash generation supports debt reduction, funding of pipeline programs and commercialization (notably Afrezza and FURO6) without sole reliance on dilutive equity financing in the near term.
Durable Partnerships & Manufacturing ContractsLong-term supply agreements and collaboration economics (royalties, upfronts, milestones) create recurring, predictable revenue streams beyond direct product sales. Sole-manufacturer status and partner payments (e.g., upfronts/milestones) strengthen revenue visibility and leverage MannKind's inhalation platform for third-party demand.
Bears Say
Persistent Negative Shareholders' EquityChronic negative shareholders' equity is a structural financial weakness that reduces balance-sheet resilience. It constrains borrowing capacity, increases refinancing and dilution risk, and weakens the firm's ability to absorb setbacks or fund sustained commercialization and R&D without external capital or dilutive transactions.
Earnings Volatility And Recent Return To Net LossWide swings between profit and loss despite revenue growth signal earnings instability. This volatility complicates multi-year planning, raises the likelihood of intermittent external financing, and means operating leverage from margins can be offset by episodic commercial spend, integration costs, or R&D investment.
Manufacturing And Access VariabilityProduction scheduling variability and related manufacturing revenue swings create revenue unpredictability for partner-derived income. Coupled with access hurdles (high prior-authorization rates for FURO6) and field reorganization disruptions, these structural execution issues can slow adoption and make near-term revenue streams less reliable.
MannKind News
NNFN FAQ
What was Mannkind Corp.’s price range in the past 12 months?
Mannkind Corp. lowest stock price was €1.93 and its highest was €5.24 in the past 12 months.
What is Mannkind Corp.’s market cap?
Mannkind Corp.’s market cap is €1.08B.
When is Mannkind Corp.’s upcoming earnings report date?
Mannkind Corp.’s upcoming earnings report date is Aug 05, 2026 which is in 3 days.
How were Mannkind Corp.’s earnings last quarter?
Mannkind Corp. released its earnings results on May 06, 2026. The company reported -€0.043 earnings per share for the quarter, missing the consensus estimate of €0 by -€0.043.
Is Mannkind Corp. overvalued?
According to Wall Street analysts Mannkind Corp.’s price is currently Undervalued.
Does Mannkind Corp. pay dividends?
Mannkind Corp. does not currently pay dividends.
What is Mannkind Corp.’s EPS estimate?
Mannkind Corp.’s EPS estimate is >-0.01.
How many shares outstanding does Mannkind Corp. have?
Mannkind Corp. has 319,391,000 shares outstanding.
What happened to Mannkind Corp.’s price movement after its last earnings report?
Mannkind Corp. reported an EPS of -€0.043 in its last earnings report, missing expectations of €0. Following the earnings report the stock price went up 10.357%.
Which hedge fund is a major shareholder of Mannkind Corp.?
Currently, no hedge funds are holding shares in DE:NNFN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MannKind Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€7.64 (127.36% Upside)
€7.64 (127.36% Upside)
Blogger Sentiment
Bullish
DE:NNFN Sentiment 75%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
1.22%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
81.50%
Trailing 12-Months
Company Description
Mannkind Corp.
MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.
NNFN Company Deck
NNFN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted multiple near-term commercial and clinical catalysts, solid top-line growth (15% YoY) and strong operational wins (FURO6 prescriber growth, royalties up 9%, SC Pharma synergies exceeding $20M), alongside meaningful progress on pipeline programs (MNKD-201 Phase 1b and Phase 2 start) and an expanded collaboration with United Therapeutics (ralinepag DPI payment and milestone potential). Short-term challenges include seasonality, field reorganization and inventory transitions that pressured Q1 revenue and contributed to GAAP and non-GAAP losses, plus some formulation and development uncertainty for new DPI programs. Management reiterated full-year FURO6 guidance and expects acceleration in H2 tied to the ReadyFlow auto-injector and Afrezza pediatrics launch, indicating confidence that near-term investments will drive longer-term growth.View all DE:NNFN earnings summariesNNFN Stock 12 Month Forecast
Average Price Target
€7.64
▲(127.36% Upside)
Technical Analysis
BioCryst
―
Celldex
―
Sarepta Therapeutics
―
Cogent Biosciences
―
Immunocore Holdings
―